Dechra Veterinary Products

Dechra Pharmaceuticals is a major global player in the veterinary medicine sector, specializing in the development, manufacture, and marketing of high-quality products for veterinarians. Founded in 1997 through a management buyout of the veterinary division of Lloyds Chemist PLC in the United Kingdom, the company has grown significantly through strategic acquisitions across Europe, North America, and South America.

Today, Dechra operates a sophisticated global supply chain. Its primary manufacturing sites are located in Skipton (UK) and Bladel (Netherlands), with additional production facilities in Melbourne (USA), Fort Worth (USA), and Londrina (Brazil). The company provides a wide range of treatments for both companion animals and food-producing animals, including therapy for endocrinology, dermatology, and pain management.

In January 2024, Dechra underwent a significant ownership change when it was delisted from the London Stock Exchange and taken private. It was acquired for approximately £4.5 billion by a consortium led by the Swedish private equity firm EQT, in partnership with Luxinva, a subsidiary of the Abu Dhabi Investment Authority (ADIA). As of 2026, the company continues to operate under this private ownership, focusing on long-term growth and innovation in the animal health market.